Given this, we chose to employ the PARPi olaparib in 769-P LV-SH FTO and 769-P LV-SH control to investigate the impact of FTO knockdown on genome stability maintenance in ccRCC cells. Here, FTO is linked to nonpapillary renal cell carcinoma.